TELMISARTAN EFFECT IN HYPERTENSION ASSOCIATED WITH DYSLIPIDEMIA

Hypertension and dyslipidemia are two major risk factors for cardiovascular diseases and commonly occur together. Dyslipidemia is a primary,widely established as an independent major risk factor for coronary heart disease. Management of dyslipidemia in hypertension patients significantly decreases the total cardiovascular risk. Peroxisome proliferator-activated receptors [PPARs] belong to the nuclear family of ligand activated transcriptional factors and comprise three different isoforms, PPAR-𝛼, PPAR-𝛽/𝛿, and PPAR-𝛾. The main role of PPARs is to regulate the expression of genes involved in lipid and glucose metabolism. Several studies have demonstrated that PPAR agonists improve dyslipidemia and glucose control in animals, supporting their potential as a promising therapeutic option to treat diabetes and dyslipidemia. PPAR-𝛾, the best characterized of the PPARs, plays a crucial role in adipogenesis and insulin sensitization.Telmisartan, an angiotensin receptor blocker [ARB] that is highly selective for AT1 receptor has been found to be a PPAR-𝛼 agonist and a selective PPAR-G modulator. This unique action of telmisartan on PPAR leads to favourable effects on lipid and carbohydrates metabolism which is independent of BP lowering effect. This provides additional benefit in treatment of dyslipidemia. Keywords: Telmisartan, Hypertension, Dyslipidemia, PPAR.